Latest News

Wednesday, June 20, 2018

Impulse Control Disorders More Common in People Who Take Dopamine Agonists

A French study which followed 411 people for an average of three years who had been diagnosed with Parkinson’s disease (PD) within 5 years, has reported an increase in impulse control disorders …

Read the full story

Friday, June 15, 2018

Ketamine Guidelines for Acute Pain Management Established and Released for the First Time

Intravenous (IV) ketamine has been used to treat acute pain in multiple conditions including as a stand-alone treatment, and as an adjunct to opioids. Ketamine is increasingly being used in both inpat…

Read the full story

Thursday, June 14, 2018

Eisai Inc Launching Center for Genetics-Guided Dementia Discovery Center

Eisai Inc (Woodcliff Lake, NJ), the U.S. pharmaceutical subsidiary of Eisai Co, Ltd, has announced that the company is committing over $100 million as an initial investment to fund the Eisai Center fo…

Read the full story

Wednesday, June 13, 2018

Medtronic Deep Brain Stimulation (DBS) Clinician Programmer Receives FDA Approval

Medtronic announced that the U.S. Food and Drug Administration (FDA) had recently approved its Deep Brain Stimulation (DBS) Clinician Programmer and Activa Programming Application. The Activa Programm…

Read the full story

Wednesday, June 13, 2018

Risk for Parkinson’s Disease May Be Linked to an Earlier Diagnosis of Diabetes

A study from England published online in Neurology on June 13 suggests that people with type 2 diabetes may have an increased risk of developing Parkinson’s disease (PD) later in …

Read the full story

Wednesday, June 13, 2018

Atogepant Demonstrates Efficacy and Safety for Prevention of Episodic Migraine

In a phase 2b/3 clinical trial (CGP-MD-01) of the orally administered calcitonin gene-related peptide receptor (CGRP) antagonist, atogepant (Allergan, Ireland), all primary endpoints for all doses and…

Read the full story

Tuesday, June 12, 2018

Clinical Trials for Lanabecestat for Treatment of Alzheimer’s Disease Discontinued

Phase 3 clinical trials for lanabecestat (Lilly, Indianapolis, IN and AstraZeneca, Wilmington, DE) for the treatment of patients with Alzheimer’s disease (AD) are being discontinued. An independ…

Read the full story

Wednesday, June 06, 2018

Black and Hispanic People May Be More Likely to Have a Second Hemorrhagic Stroke than Whites

Results from a study published online in the journal Neurology suggest that black and Hispanic people may be more likely to have a second hemorrhagic stroke compared to white people who have had a hem…

Read the full story

Tuesday, June 05, 2018

Patients Treated With Lemborexant Awake and Return to Sleep Safely Without Fall Risk

In results presented today at the Associated Professional Sleep Societies meeting (SLEEP 2018, Baltimore, MD) it was shown that patients treated with lemborexant (Eisai, Woodcliff Lake, NJ and Purdue …

Read the full story

Tuesday, June 05, 2018

American Academy of Sleep Medicine Issues Advisory: Insufficient Sleep May Increase Risk for Alzheimer’s Disease

The American Academy of Sleep Medicine (AASM) has issued a health advisory warning that insufficient or poor sleep may increase the risk of developing Alzheimer’s disease (AD). The AASM believes…

Read the full story

Monday, June 04, 2018

Excessive Sleepiness Impacts More Than Quality of Life: More Awareness Needed

Results from a survey of sleep specialists suggest there is a need for greater awareness of the neurologic effects of excessive sleepiness (ES), including neuronal injury and neurocognitive impairment…

Read the full story

Monday, June 04, 2018

Medicare Benefit Coverage Available for MR-Guided Focused Ultrasound to Treat Essential Tremor

Magnetic resonance (MR)-guided focused ultrasound (MRgFUS) (INSIGHTEC, Miami, FL) for the treatment of essential tremor is now available as a medicare benefit in 10 states: Connecticut, Maine, New Ham…

Read the full story

Friday, June 01, 2018

BrainStorm to Host Phone Discussion of Right to Try Legislation and Stem Cell Therapy June 7th

Brainstorm Cell Therapeutics Inc (New York, NY) will host a phone call on June 7th at 8:15 AM EDT to provide interested parties an opportunity to engage with the company regarding new “right-to-…

Read the full story

Friday, June 01, 2018

Results for Cladribine For MS Presented at CMSC

Data on use of cladribine tablets (EMD Serono, Rockland, MA) for treatment of relapsing multiple sclerosis (MS) were presented at the Consortium of Multiple Sclerosis Centers (CMSC) meeting in Nashvil…

Read the full story

Thursday, May 31, 2018

FDA Grants Clearance for Fully Implantable Wireless Intracranial Pressure Sensor

The AURA intracranial pressure (ICP) monitoring system (Branchpoint Technologies, Irvine, CA) has been granted clearance by the Food and Drug Administration (FDA). This first of kind system is fully i…

Read the full story
Load More